Oblique
      Vision
      Idea and vision

      Oblique Therapeutics:

      • is a curiosity-driven, innovative biotech company with strong scientific acumen and drive for increasing the bandwidth of antibody therapeutics, focusing on pain and aggressive metastatic cancer.
      • has a vision to be a global industry leader focused on transformative antibody medicines against pain and aggressive cancer.
      • aims at 2–3 antibody drug approvals per year within 10 years.

      Highlighted programs in the pipeline

      aKRAS: a portfolio of aG13D, aG12D and aG12V mAbs intended for treatment of aggressive cancer

      Oblique has developed a pipeline of mutant selective aKRAS mAbs where the most advanced program targeting the KRAS G13D mutation has shown efficacy in a colorectal cancer xenograft model.

      aTRPV1: Partnered asset intended for treatment of pain

      Oblique Therapeutics has developed high affinity, stimuli-selective antibodies against the pain receptor TRPV1 in order to maximize pain relief and circumvent side effects. This asset is currently partnered with a top-20 pharma company.

      aTRX mAb: Intended for treatment of TNBC

      Oblique has identified several potent aTRX mAbs that bind and neutralize Trx1 activity. These antibodies are being evaluated for immune modulation and anti-tumor activity